Jan

2012

Neuraltus Pharmaceuticals, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q11, R - WEST, X - ALS, X - Alzheimer's, X - Lysosomal Storage, X - Multiple Sclerosis, X - Neuro Degenerative, X - Parkinson's, XX - CA

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Apr

2011

Civitas Therapeutics, Inc.: Series A $20M

Posted in I - Series A, Q - 1Q11, R - NORTH EAST, X - Device (Delivery), X - Drug:Device Combo, X - Parkinson's, XX - MA

Civitas Therapeutics (Chelsea, MA) a preclinical-stage dry powder pulmonary delivery platform and device combination company focused on for Parkinson’s disease, closed a $20M Series A financing. Participants include Longitude Capital and Canaan Partners.

Jan

2011

Mind-NRG, SA: Series A $2M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Alzheimer's, X - CNS, X - Parkinson's, X - Schizophrenia

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Dec

2010

Ceregene, Inc.: Series D $11.5M

Posted in I - Series D, Q - 4Q10, R - WEST, X - Alzheimer's, X - Gene Therapy, X - Parkinson's, XX - CA

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Oct

2010

iPierian, Inc.: Series B $6M

Posted in I - Series B, Q - 3Q10, R - WEST, X - ALS, X - Parkinson's, X - Stem Cell, XX - CA

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins [...]

Aug

2010

iPierian, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q10, R - WEST, X - ALS, X - Parkinson's, X - Stem Cell, XX - CA

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

Apr

2010

Archimedes Pharma, Ltd.: Series C $99M

Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - Oncology, X - Pain, X - Parkinson's, X - Vaccines

Archimedes Pharma (United Kingdom) a commercial-stage specialty oncology company focused on pain and critical care, closed a $99M Series C financing. Participants include Novo Growth Equity and Warburg Pincus.

Oct

2009

Adamas Pharmaceuticals, Inc.: Series D $40M

Posted in I - Series D, Q - 3Q09, R - WEST, X - Antiinfective, X - CNS, X - Dementia, X - Influenza, X - Parkinson's, XX - CA

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Jun

2009

Avid Radiopharmaceuticals, Inc.: Series D $34.5M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Mar

2009

Heptares Therapeutics, Ltd.: Series A $29.9M

Posted in I - Series A, Q - 1Q09, R - INTERNATIONAL, X - G-Protein, X - Parkinson's

Heptares Therapeutics (United Kingdom) a discovery-stage company focused on small-molecule drugs targeting G-protein-coupled receptors whose lead indication is Parkinson’s, closed a $29.9M Series A financing. Participants include Clarus Ventures, MVM Life Science Partners and Novartis Ventures Option Fund.

Jan

2009

Satori Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Alzheimer's, X - Neurology, X - Parkinson's, XX - CA

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

to top of page...